Please check your internet connection and try again.
# Ticagrelor (Brilinta)
## Overview
Ticagrelor is an oral, direct-acting P2Y12 platelet inhibitor. It is a member of the cyclopentyltriazolopyrimidine (CPTP) class.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** In combination with aspirin, for the prevention of thrombotic events (e.g., cardiovascular death, myocardial infarction, stroke) in patients with ACS.
* **Myocardial Infarction (MI):** In combination with aspirin, for the prevention of thrombotic events in patients with a history of MI.
## Adult Dosing
* **ACS:** 180 mg orally once as a loading dose, followed by 90 mg orally twice daily for up to 12 months.
* **History of MI:** 60 mg orally twice daily.
* **Maintenance dose for ACS patients after the initial 12 months:** If patients are treated with ticagrelor 90 mg twice daily for ACS and are continuing treatment after 12 months, ticagrelor 60 mg twice daily may be considered.
## Pediatric Dosing
There is no established pediatric dosing for ticagrelor.
## Dose Adjustments
No dose adjustments are required for renal or hepatic impairment. However, caution is advised in moderate to severe hepatic impairment.
## Contraindications
* Hypersensitivity to ticagrelor or any component of the formulation.
* Active pathological bleeding.
* History of transient ischemic attack (TIA) or stroke while on ticagrelor therapy (consider risks vs benefits).
## Adverse Effects
* **Bleeding:** The most common and serious adverse effect. Can occur at any site (e.g., gastrointestinal, intracranial, epistaxis, hematuria).
* **Dyspnea:** May occur and is usually transient.
* **Bradycardia:** Transient symptomatic bradycardia can occur.
* **Hyperuricemia:** Elevated uric acid levels.
* **Anemia:** Decreased hemoglobin.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase ticagrelor exposure and risk of bleeding. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) may decrease ticagrelor exposure.
* **Other Antiplatelet Agents and Anticoagulants:** Increased risk of bleeding. Use with caution and consider the duration of dual antiplatelet therapy (DAPT) based on individual risk.
* **Aspirin:** Often used in combination for ACS and post-MI patients. While synergistic for efficacy, it increases bleeding risk.
* **Statins:** Rosuvastatin and simvastatin (CYP3A4 substrates) may have increased exposure when coadministered with ticagrelor; dose adjustments may be needed.
## Monitoring
* **Signs and Symptoms of Bleeding:** Monitor closely for any signs of bleeding (e.g., bruising, hematuria, melena, epistaxis).
* **Hemoglobin/Hematocrit:** Monitor periodically, especially in patients at high risk of bleeding.
* **Platelet Function Tests:** May be used in select situations, but clinical bleeding is the most important indicator of efficacy/safety.
## Clinical Pearls
* Ticagrelor is a P2Y12 inhibitor that is reversible and not a prodrug, unlike clopidogrel.
* The loading dose of 180 mg is crucial for patients with ACS.
* Maintenance dose for ACS is 90 mg BID for up to 12 months. Consider 60 mg BID after 12 months for long-term prevention.
* The 60 mg BID dose is indicated for patients with a history of MI.
* Discontinue ticagrelor at least 5 days prior to elective surgery if possible, but balance this against the risk of ischemic events.
* Patients experiencing dyspnea should be assessed for other causes, but if no other cause is found, ticagrelor may be continued if benefits outweigh risks.
* Ticagrelor is not recommended for use with a P2Y12 inhibitor loading dose in patients already receiving a P2Y12 inhibitor.
***
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult with a qualified healthcare provider for any questions regarding a medical condition or treatment. Verify current prescribing information with the manufacturer's official documentation.*
